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Abstract
The United States Supreme Court delivered its much-anticipated judgment in the 
case of Mayo Collaborative Services v. Prometheus Laboratories, Inc. on March 20, 2012. 
The judgment has triggered a spate of commentary from legal scholars and legal 
practitioners supporting and opposing the decision. One point about which there is 
unanimity is that the Supreme Court’s judgment is of great significance inasmuch as it 
reconfigures the law relating to subject matter patent eligibility. The Mayo v. 
Prometheus case involved patents on a medical process for determining the appropriate 
level of dosage of synthetic drugs called thiopurines for individuals having certain 
autoimmune-related sicknesses. The judgment is bound to be of great significance to 
the biotechnology and pharmaceutical industries and will have an effect on the 
provision of health care and the development of medical diagnostic techniques. It 
could also have important consequences for other process patents such as computer- 
based business method and software-related patents. Extending the doctrines and 
principles relating to subject matter patent eligibility laid down in leading precedents, 
the U.S. Supreme Court clarified the standards relating to the exclusion of patent 
eligibility under Section 101 of the U.S. Patent Act. This essay sets out the 
development of the U.S. Supreme Court’s jurisprudence relating to subject matter 
patent-eligibility and the contours of such eligibility as they have now taken shape in 
the wake of the Court’s judgment in Mayo v. Prometheus. Due to the transnational 
repercussions of patent law, the essay sets out the position in law relating to subject 
matter patent eligibility in the two other major areas in respect of patent law, namely, 
Japan and the member states of the European Patent Organisation. Finally, the paper 
sets out some personal observations and comments regarding the judgment. 
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Companies achieve competitive advantage through acts of 
innovation. They approach innovations in its broadest sense,
including both new technologies and new ways of doing things.
They perceive a new basis for competing or find better means 
for competing in old ways. Innovation can be manifested in a new
product design, a new production process, a new marketing 
approach, or a new way of conducting training. 
                                                            Michael E. Porter1
Michael E. Porter, The Competitive Advantage of Nations, 
Harvard Business Review, March 1990.
I. Introduction:
The United States Supreme Court delivered its much anticipated judgment in the 
case of Mayo Collaborative Services v. Prometheus Laboratories, Inc.2 on March 20, 2012. 
The judgment has triggered considerable commentary from legal scholars and legal 
practitioners supporting and opposing the decision. One point about which there is a 
general consensus is that the Supreme Court’s judgment is of great significance in 
shaping the continually evolving contours of subject matter patent-eligibility. The 
Mayo v. Prometheus case involved patents on a medical diagnostic process for 
determining the appropriate level of dosage of synthetic drugs called thiopurines for 
individuals having certain autoimmune related illnesses. The judgment is expected to 
have repercussions on the biotechnology and pharmaceutical industries and also have 
consequences on the development of medical diagnostics and the provision of health 
care. It could also have an effect on computer-based business method and software-
related patents and the continuing validity of process patents in a host of other fields. 
Extending the doctrines and principles relating to subject-matter eligibility as laid 
down in the leading cases of Gottschalk v. Benson, Parker v. Flook, Diamond v. Diehr, 
and Bilski v. Kappos, clarified the standards governing the exclusion of “laws of nature” 
from patent eligibility under Section 101 of the U.S. Patent Act. 
 1  Michael E. Porter, The Competitive Advantage of Nations, Harvard Business Review, March-
April 1990, at page 75.
 2  Mayo Collaborative Services, et al. v. Prometheus Laboratories, Inc. Slip Opinion, cited as 566 
U.S.          (2012). Available at: http://www.supremecourt.gov/opinions/11pdf/10-1150. 
pdf.
105BULLETIN OF KYUSHU WOMEN'S UNIVERSITY     Vol.49 No.1
Patent law is one species of the larger category of intellectual property law. 
Patent law has ramifications that go beyond the rights of patent-holders. Its purpose is 
to serve as an incentive to spur innovation and creativity with the ultimate aim that 
that will in turn benefit society at large. Under patent law, innovators are granted the 
exclusive right to the use of their inventions for a specified period of time in exchange 
of which the innovator is obliged to disclose the details of the invention. By doing 
this, the law recognizes the moral and economic rights that flow to the innovator as 
the fruits of his or her labor. At the same time, it promotes the interests of society 
because of the social benefit that accrues and the economic productivity that is 
enhanced as a result of the creation of new products and designs. It further serves the 
societal interest by means of the dissemination of knowledge regarding the invention 
and the freedom to use that knowledge after the lapse of the inventor’s exclusive right 
at the end of the stipulated period. But these benefits have to be balanced at all times 
with the anti-competitive effects and the resultant costs to society that flow from the 
grant of exclusive rights.
Article 7 of the World Trade Organization’s Agreement on Trade Related Aspects 
of Intellectual Property Rights sets out the aims of the regime of intellectual property 
rights thus:
The protection and enforcement of intellectual property rights 
should contribute to the promotion of technological innovation
and to the transfer and dissemination of technology, to the 
mutual advantage of producers and users of technological
knowledge and in a manner conducive to social and economic
welfare, and to a balance of rights and obligations.3 
Innovation is one of the vital engines of economic growth and international 
competitiveness. As Michael Porter, a world authority on competitiveness has pointed 
out in the lines that serve as the epigraph to this essay, innovation takes many forms. 
However, not all inventions are patentable. Different jurisdictions have different laws 
regarding what innovations are patentable and what innovations are excluded from 
the province of patentable subject matter. The determination as to what should be 
 3  Article 7, Objectives, Agreement on Trade Related Aspects of Intellectual Property 
Rights (the TRIPS Agreement). Available at: http://www.wto.english/tratop_e/trips_e/t_
agm2_e.htm.
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included within the domain of patentable subject matter is made on the basis of a 
balance between a nation’s larger economic interests and moralistic considerations. 
Due to the transnational effects of patent laws, such differences assume greater than 
normal significance. It is these transnational effects that have lent the impetus for the 
drive to effectuate harmonization of each component of intellectual property laws 
among the nations of the world.4 This movement has been proceeding within the 
realm of patent law along separate tracks for procedural matters and substantive 
matters. 
After the present introduction, part II of this essay sets out the development of the 
U.S. Supreme Court’s jurisprudence relating to subject matter patent eligibility and the 
contours of such eligibility as they have now taken shape in the wake of the Court’s 
judgment in Mayo v. Prometheus. Part III sets out the present international situation in 
respect of subject-matter patent eligibility with specific reference to the patentability of 
medical diagnostic methods similar to those at issue in the Mayo case. Of particular 
importance is the presently prevailing situation in Japan and the member states of the 
European Patent Organization. Part IV sets out a few brief personal observations 
regarding the judgment in Mayo v. Prometheus. Finally, the essay ends with a 
conclusion.
II . An Outline of the Jurisprudence Relating to Subject Matter Patent-
Eligibility in the United States:
Patent Law in the United States is based upon one of the enumerated powers of 
the U.S. Congress under Article 1 of the U.S. Constitution. Specifically, Article 1, 
Section 8, Clause 8 of the U.S. Constitution states: “The Congress shall have power... 
To promote the Progress of Science and useful Arts, by securing for limited Times to 
 4  See, e.g., the remarks of David Kappos, the Director of the USPTO at the World 
Intellectual Property Symposium, on Sept. 22, 2011. “Promoting Innovation & 
Creativity: The America Invents Act and a Global Call for Harmonization”:
The public must have confidence that the patent system is striking
the right balance between incentives to innovate and access to those
new innovations. Through global synergy and collaboration, we have a
unique opportunity, right away, to meet these challenges --- and I believe
it is imperative we do that, and act by moving towards a more
standardized global patent system.
 Available at: http:www.uspto.gov/news/speeches/2011/kappos_wipo.jsp). 
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Authors and Inventors the exclusive Right to their respective Writings and 
Discoveries.” The U.S. Supreme Court has said that this clause “reflects a balance 
between the need to encourage innovation and the avoidance of monopolies which 
stifle competition without any concomitant advance in the ‘Progress of Science and 
useful Arts.’” 5 
The U.S. Patent Act is contained in Title 35 of the United States Code. Sections 
101, 102, 103, and 112 set out the requisites for patent eligibility.6 
Section 101 describes patentable subject matter as the discovery or invention of 
“any new and useful process, machine, manufacture, or composition of matter, or any 
new and useful improvement thereof.”7 Section 102 sets out “novelty” as one of the 
conditions for patent eligibility. Section 103 adds the further condition that the claimed 
subject matter should not have been obvious at the pertinent time “to a person having 
ordinary skill in the art.”8 Section 112 requires that the patent application should 
clearly describe the claimed invention and “the manner and process of making and 
using it.”
Section 101 defines the scope of what counts as patentable subject matter. It is 
commonly viewed as serving the function of a gatekeeper screening the category of 
 5  Bonito Boats v. Thunder Craft Boats, 489 U.S. 141, 146 (1989).
 6  For the purposes of this paper, the definition of “process” is also important. Section 100 
(b) defines it thus: “The term ‘process’ means process, art or method, and includes a new 
use of a known process, machine, manufacture, composition of matter, or material.”
 7  The previous Patent Act contained the word “art” which was replaced by the word 
“process” in the Patent Act of 1952. Prior to the change, in the 1876 case of Cochrane v. 
Deener, 94 U.S. 780, 780 (1876), the U.S. Supreme Court had described process as “a 
mode of treatment of certain materials to produce a given result,” and that “it is an act, 
or a series of acts, performed upon the subject matter to be transformed and reduced to a 
different state or thing.”
 8  In an important recent judgment relating to the scope of the obviouness inquiry, the U.S. 
Supreme Court observed in KSR International Company v. Teleflex Inc., et al., 550 U.S. 398, 
as follows:  
We build and create by bringing to the tangible and palpable reality
around us new works based on instinct, simple logic, ordinary inferences,
extraordinary ideas, and sometimes even genius. These advances, once
part of our shared knowledge, define a new threshold from which 
innovation starts once more. And as progress from higher levels of 
achievement is expected in the normal course, the results of ordinary
innovation are not the subject of exclusive rights under the patent laws.
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claims that will be admitted for patent consideration.9 For example, as early as 1852, 
the U.S. Supreme Court had observed in Le Roy v. Tatham that an abstract principle 
was unpatentable.10
Following is a list of some of the most significant cases relating to subject matter 
patent-eligibility after the enactment of the U.S. Patent Act of 1952.
1. Gottschalk v. Benson :11 
This case involved a patent application for a algorithm-based method whereby 
binary-coded decimal numerals were converted to pure binary numerals, without the 
method being tied to any specific apparatus, machinery, or technology. The U.S. 
Supreme Court was required to decide whether the claimed method was a patentable 
process under Section 101 of the U.S. Patent Act. Based upon an extensive review of 
the case law, the Court noted that “[p]henomena of nature, though just discovered, 
mental processes, and abstract intellectual concepts are not patentable, as they are the 
basic tools of scientific and technological work,”12 unless there was a consequent 
“application of the law of nature to a new and useful end.”13 In the present case the 
process claim was too abstract and wide-ranging, and the grant of a patent would be 
tantamount to a patent on the algorithm, which would run afoul of the proscription 
against the patenting of an idea. 
2. Parker v. Flook :14 
The case involved the patent-eligibility of a method based upon a mathematical 
formula, whereby appropriate alarm limits could be updated in certain industrial 
settings. The Court relied upon Gottschalk v. Benson, which it read as having held that 
a mathematical formula was akin to a law of nature and therefore could not be the 
subject matter of a patent.15 In this case, since the mathematical formula was assumed 
 9  See Mark A. Lemley, Michael Risch, Ted Sichelman & R.Polk Wagner, Life After Bilski, 
63 Stanford Law Review 1315, at 1326.
10  Le Roy v. Tatham, 55 U.S. (14 How). 156 (1852).
11  Gottschalk v. Benson, 409 U.S. 63 (1972).
12  Id.,at 67.
13  Id., quoting the opinion of the U.S. Supreme Court in Funk Bros. Seed Co. v. Kalo Co., 333 
U.S. 127, 130.
14  Parker v. Flook, 437 U.S. 584 (1978).
15  Id., at 589.
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to be part of the prior art, the Court16 held that the mere addition of some non-
inventive subsequent activity could not make it patentable under Section 101 of the 
U.S. Patent Act (35 U.S.C. 101).17 
3. Diamond v. Chakrabarty :18 
This case involved the patentability of a genetically engineered bacterium. The 
question at issue was whether a living micro-organism could be validly interpreted as a 
patentable manufacture or a composition of matter within the meaning of 35 U.S.C. 101. 
After reviewing the relevant case law and the legislative history of the germane legal 
provisions, the Court held that the micro-organism in question was patentable subject 
matter as it was a product of human invention and not a natural phenomenon.19 
4. Diamond v. Diehr :20 
This case involved a patent on an industrial process which employed the use of a 
mathematical formula as one of the steps in the process. Clarifying  the Court’s previous 
opinions in Gottschalk v. Benson and Parker v. Flook, the Court held that the mere 
presence of a mathematical formula as one step in a process claim does not invalidate 
the claim. The claimed process must be considered in its totality. If the process performs 
a patentable function, then it is patentable subject matter not with standing the use of 
16  The opinion of the Court was written by Justice Stevens. Justices Brennan, White, 
Marshall, Blackmun, and Powell joined in the opinion. 
17  Three Justices dissented. Justice Stewart’s dissenting opinion, joined in by Chief Justice 
Burger and Justice Rehnquist considered the claimed process as falling within the 
bounds of subject-matter patentability under Section 101. 
18  Diamond v. Chakrabarty, 447 U.S. 303 (1980).
19  The opinion of the Court contained a widely cited statement that “[t]he Committee 
Reports accompanying the 1952 Act inform us that Congress intended statutory subject 
matter to ‘include anything under the sun that is made my man.’ “Id. at 309．The 
opinion of the Court was written by Chief Justice Burger, with Justices Stewart, 
Blackmun, Rehnquist and Stevens joining in. Justice Brennan dissented, with Justices 
White, Marshall, and Powell joining in his dissenting opinion. 
20  Diamond v. Diehr, 450 U.S. 175 (1981). Justice Rehnquist wrote the opinion of the Court, 
with Chief Justice Burger, and Justices Stewart, White and Powell joining in. Justice 
Stevens dissented, with Justices Brennan, Marshall, and Blackmun joining in Justice 
Stevens’s dissenting opinion. 
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the mathematical formula.21.
5. Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc. :22  
It will be useful to mention here a case where a similar question was involved and 
in which a certiorari had been granted but was later dismissed by a majority of the 
Court without going into the merits of the case. However, three Justices dissented 
stating that a resolution of the question at issue would benefit medical practitioners 
and researchers and members of the general public that seek proper health care. Justice 
Breyer wrote the dissenting opinion, with Justices Stevens and Justice Souter 
joining. The dissenting Justices were of the view that the claimed process in the case 
was unpatentable as it was merely a “natural phenomenon.” Of particular significance 
was the policy consideration that the dissenting judgment sought to canvass. 
According to the dissenting view, if the patent in that case were not held invalid, it 
would
leave the medical profession subject to the restrictions imposed
by this individual patent and others of its kind. Those restrictions
may inhibit doctors from using their best medical judgment; they
may force doctors to spend unnecessary time and energy to enter
into license agreements; they may divert resources from the medical
task of health care to the legal task of searching patent files for 
similar simple correlations; they may raise the cost of healthcare
while inhibiting its effective delivery.23 
21  The Court made particular reference to Justice Stone’s opinion in Mackay Radio & 
Telegraph Co. v. Radio Corp. of America, 306 U.S.86 (1939) as taking the Court “a long 
way” to the resolution of the issue in the case. The Court quoted Justice Stone’s 
following observation: “While a scientific truth, or the mathematical expression of it, is 
not a patentable invention, a novel and useful structure created with the aid of 
knowledge of scientific truth may be.” Diamond v. Diehr, 450 U.S. 175, at 190 (1981).
22  Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124 (2006), 
126 S.Ct. 2921.
23  Id., at 138. In the penultimate paragraph of the dissenting opinion, Justice Breyer makes 
a percipient reference to specialists and generalists and the varying opinions among 
both groups regarding the adequacy of the current patent system in the United States. 
The opinion cites the need to preserve the “careful balance” referred to by the Court in 
Bonito Boats Inc. v. Thunder Craft Inc., 489 U.S. 141,146 (1989). In that judgment the Court 
had stated: “From their inception, the federal patent laws have embodied a careful 
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6. Bilski v. Kappos :24 
This case involved a claimed method for efficient buying and selling when trading 
in the energy market.25 The United States Court of Appeals for the Federal Circuit had 
departed from the test that it had earlier used to determine patentability under Section 
101 of the U.S. Patent Act.26 In its stead, the Federal Court postulated the “machine-or-
transformation” test as the only test for determining patentability under Section 101,27 
and on that footing held the claimed method to be subject matter that was ineligible 
for patent protection. On appeal, the U.S. Supreme Court held that though it was an 
important factor to be considered, the machine-or-transformation test was not the only 
test for determining patent-eligibility of processes under Section 101.28 The Court also 
refused to exclude business methods from the ambit of patentable subject matter under 
balance between the need to promote innovation and the recognition that imitation and 
refinement through imitation are both necessary to invention itself, and the very 
lifeblood of a competitive economy.”
24  Bilski v. Kappos, Slip opinion, 561 U.S.          (2010), available at :
 http:www.supremecourt.gov/opinions/09pdf/08-964.pdf.
25  Claim 1 of the patent at issue as quoted in the Supreme Court opinion is as follows:
Claim 1 consists of the following steps:
“(a) initiating a series of transactions between said commodity
provider and consumers of said commodity wherein said consumers
purchase said commodity at a fixed rate based upon historical averages,
said fixed rate corresponding to a risk position of said consumers;
“(b) identifying market participants for said commodity having a 
counter-risk position to said consumers; and 
“(c) initiating a series of transactions between said commodity provider
and said market participants at a second fixed rate such that said 
series of market participant transactions balances the risk position of
said series of consumer transactions.” App. 19-20.
 Bilski v. Kappos, id., at internal page 2 of the opinion of the Court (Slip opinion).  
26  The then prevailing test was whether the claimed process had the effect of producing a 
“useful, concrete, and tangible result.” This test was propounded and used by the 
Federal Court in State Street Bank & Trust Co. v. Signature Financial Group, Inc. 149 F. 3d 
1368, 1373 (1998) and AT&T Corp. v. Excel Communications, Inc., 172 F. 3d 1352, 1357 
(1999). 
27  Under the machine-or-transformation test, a process would be patentable if “(1) it is tied 
to a particular machine or apparatus, or (2) it transforms a particular article into a 
different state or thing.” 545 F. 3d, at 954.
28  The Court reasoned that the machine-or-transformation test, although appropriate for the 
Industrial Age, was anachronistic for the Information Age inasmuch as it “would create 
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Section 101.29 Instead, the Court followed the principle laid down in Gottschalk v. 
Benson, Parker v. Flook, and Diamond v. Diehr and held the claimed method in this case 
to be ineligible for a patent as it was, in essence, no more than an abstract idea.30 
7. Mayo Collaborative Services v. Prometheus Laboratories, Inc. :31 
This case involved two patents on a process whereby doctors could determine the 
appropriate level of dosage of synthetic drugs called thiopurines to be administered for 
individuals with certain autoimmune problems. The process was embodied in a 
thiopurine metabolites test kit. The metabolite levels in the individual’s blood stream 
that resulted from the metabolism of a given dose of thiopurine drug served as a 
pointer regarding the calibration of subsequent dosage. The claimed process involved 
the ascertainment of the metabolite levels as a consequence of the initial ingesting of a 
given dose of the thiopurine drug, and a specification of the standards above and 
below which metabolite levels showed a need for adjustment of the subsequent 
dosage.32 Prometheus Laboratories, Inc. was the sole license holder of the patents. The 
uncertainty as to the patentability of software, advanced diagnostic medicine techniques, 
and inventions based on linear programming, data compression, and the manipulation of 
digital signals. Bilski v. Kappos, slip opinion, 561 U.S. __ (2010), internal page 9, 130 S.Ct. 
3218. 
29  The issue of the patentability of business methods had been catapulted into prominence 
since the judgment of the United States Court of Appeals for the Federal Circuit in the 
case of State Street Bank & Trust Co. v. Signature Financial Group, Inc., 149 F.3d 1368 (Fed. 
Cir. 1998). While refusing to accept the excludability of business methods from the ambit 
of patent-eligible subject matter, the Court of Appeals stated: “Since the 1952 Patent 
Act, business methods have been, and should have been, subject to the same legal 
requirements for patentability as applied to any other process or method [internal 
footnote omitted].” 149 F.3d 1368 at 1375. The Court of Appeals later reiterated this 
view in AT&T Corp. v. Excel Communications, Inc., 172 F.3d 1352 (1999). 
30  Bilski v. Kappos reiterated the principle that a patentable claim must fall outside the 
category of unpatentable subject matter, namely, abstract ideas, laws of nature, and 
natural phenomena, that had been so designated by the Court’s precedents. Bilski v. 
Kappos, 130 S.Ct. 3218, 3225 (2010). (The majority opinion stated: “The Court’s 
precedents provide three specific exceptions to Sectio 101’s broad patent-eligibility 
principles: ‘laws of nature, physical phenomena, and abstract ideas.’”
31  Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S.          (2012) (slip 
opinion), supra note 2.
32  Claim 1 of one of the patents at issue as quoted by the Court in its judgment reads as 
follows:
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petitioner Mayo Collaborative Services, Inc.’s contention was  that doctors routinely 
checked individual reactions to drug dosages and made appropriate adjustments, and 
hence, the claimed process was patent-ineligible as it merely sought the exclusive 
right to use a technique of medical diagnosis that was commonplace in the medical 
profession and involved no innovation. 
The District Court held that the claimed process was based upon correlations 
between metabolite levels and drug dosages which were natural phenomena and 
hence ineligible for patent protection. On appeal, the U.S. Court of Appeals for the 
Federal Circuit reversed. The U.S. Court of Appeals reasoned that the initial act of 
ingesting the thiopurine drug and the checking of the resultant metabolite level which 
were steps in the claimed process involved a certain transformative aspect in respect of 
the human body. This, according to the Court of Appeals rendered the process 
patentable under the “machine-or-transformation test” and also circumscribed its ambit 
sufficiently to meet the requirements of Section 101 of the U.S. Patent Act. Upon the 
application of Mayo Collaborative Services,  the U.S. Supreme Court granted certiorari, 
and remanded the case to the Federal Court for reconsideration in light of its holding 
in Bilski v. Kappos that the “machine-or-transformation” test was an important factor to 
be considered but was not dispositive regarding patent-eligibility. Upon remand, the 
Federal Court reaffirmed its judgment. The U.S. Supreme Court once again granted 
Mayo’s petition for certiorari, and went on to hold by a unanimous decision that the 
claimed process was in essence a statement of a law of nature and hence ineligible for 
“A method of optimizing therapeutic efficacy for treatment of an immune-
mediated gastrointestinal disorder, comprising:
“(a) administering a drug providing 6-thioguanine to a subject 
having said immune-mediated gastrointestinal disorder, and
“(b)determining the level of 6-thioguanine in said subject having said
Immune-mediated gastrointestinal disorder,
“wherein the level of 6-thioguanine less than about 230 pmol per 
8+108 red blood cells indicates a need to increase the amount of said
drug subsequently administered to said subject and
“wherein the level of 6-thiogunine greater than about 400 pmol per
8+108 red blood cells indicates a need to decrease the amount of said
drug subsequently administered to said subject.” ‘623 patent, col. 20,
Il. 10-20, 2 App. 16. 
  Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S.          (2012) (slip 
opinion), at internal page 6.
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patent-protection. As the Court put it:
      Prometheus’ patents set forth laws of nature－ namely,
relationships between concentrations of certain metabolites
in the blood and the likelihood that a dosage of a thiopurine
drug will prove ineffective or cause harm.... While it takes a
human action (the thiopurine drug) to trigger a manifestation
of this relation in a particular person, the relation itself exists
in principle apart from any human action. The relation is a
consequence of the ways in which thiopurine compounds are 
metabolized by the body ― entirely natural processes. And so
a patent that simply describes that relation sets forth a 
natural law.
      The question before us is whether the claims do significantly
more than simply describe these natural relations. To put the 
matter more precisely, do the patent claims add enough to their
statements of the correlations to allow the processes they describe
to qualify as patent-eligible processes that apply natural laws?
We believe that the answer to this question is no.33 
Holding the process claim to be invalid, the Court reversed the judgment of the U.S. 
Court of Appeals.
The Supreme Court’s opinion is bound to have wide-ranging repercussions for the 
pharmaceutical industry, the medical profession, and the general public seeking 
medical help.  The wide array of amicus briefs in support of both petitioners as well as 
respondents testifies to the expected repercussions of the Supreme Court’s judgment.34 
The judgment could , inter alia, have a marked influence on the development of the 
biotechnology industry and personalized medicine whereby treatment is calibrated to 
meet the specific needs of each individual seeking treatment.35 The judgment could 
33  Id. at internal page 8.
34  In the Supreme Court there were seven amicus briefs in support of Mayo Collaborative 
Services, fifteen in support of Prometheus Laboratories, and six in support of neither 
party. Justice Breyer has observed elsewhere that amicus briefs, more than the parties’ 
briefs, indicate the wide public policy implications of the cases before the Court. See 
Stephen G. Breyer, Genetic Advances and Legal Institutions, 28 (4 Supplement) J.L. Med. & 
Ethics 23-28 (2000).
35  See, for example: Brief for Arup Laboratories, Inc. and Laboratory Corporation of 
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potentially affect the computer and software industry, too.36 
The day after the Supreme Court’s judgment, the United States Patent and 
Trademark Office issued a memorandum to guide the Patent Examining Corps in 
determining patent subject matter eligibility in the light of Mayo v. Prometheus.37 This 
was supplanted by a more detailed, memorandum seeking to serve guidance “for 
examination of process claims in which a law of nature, a natural phenomenon, or 
naturally occurring relation or correlation ... is a limiting element or step.”38 The new 
interim procedure lists three inquiries to be made for determining subject matter patent 
America Holdings (D/B/A Labcorp) as Amici Curiae in Support of Petitioners, at page 4. 
(“The preemptive effects of such patents on research, medical services and the growing 
field of personalized medicine are profound.”). Also see: Brief of the Biotechnology 
Industry Organization as Amicus Curiae In Support of Respondent. The brief states, inter 
alia, (at page 5):   
The progress of the biotechnology industry over the 30 years of its
existence has demonstrated that patent protection is an essential driver
of innovation. The role that patents have played for this industry and 
which they must play to encourage innovation in the field of 
personalized medicine, is exactly the role that the Patent Clause
envisions....Using section 101 to broadly exclude entire categories
of new and useful inventions from patent eligibility would be 
antithetical to this basic purpose. 
  Available at SCOTUS blog, http://www.scotusblog.com/case-files/cases/mayo-
collaborative-services-v-prometheus-laboratories-inc/
36  See, for example, Brief of SAP America, Inc. as Amicus Curiae In Support of Affirming 
the Federal Circuit’s Opinion. The Brief states, at page 2:
The software and computer industries are a vital part of today’s 
Information Age economy and these industries depend on patent
protection for growth and innovation. A decision regarding the scope of 
35 U.S.C. Section 101 as applied to medical diagnostic processes 
could have far-reaching effects in all technology areas, including
software and other computer-related technologies.  
37  United States Patent and Trademark Office Memorandum dated March 21, 2012, 
available at: http://www.uspto.gov/patents/law/exam/mayo_prelim_guidance.pdf.
38  United States Patent and Trademark Office Memorandum dated July 3, 2012. Subject: 
2012 Interim Procedure for Subject Matter Eligibility Analysis of Process Claims Involving Laws of 
Nature. Available at: http://www.uspto.gov/patents/law/exam/2012_interim_guidance.pdf. 
The guidelines for evaluation of process claims that involved abstract ideas as opposed 
to laws of nature continued to be the earlier issued Interim Guidance for Determining Subject 
Matter Eligibility for Process Claim in View of Bilski v. Kappos, 75 Fed.Reg.43922, July 27, 
2010 (2010 Interim Bilski Guidance).
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eligibility under Section 101. The third inquiry requires the presence of additional 
elements that apply the law of nature so that the claimed process is “significantly more 
than the natural principle itself.” This points to a considerably heightened level of 
scrutiny for examining process claims that are based upon laws of nature or naturally 
occurring phenomena.
Also of great interest to date are the Supreme Court’s rulings on petitions for 
certiorari in two significant cases involving subject matter patentability under Section 
101 of the U.S. Patent Act. In both cases, the Court granted certiorari, vacated the 
judgment of the U.S. Court of Appeals for the Federal Circuit, and remanded the cases 
to the Federal Court for further consideration in view of the judgment in Mayo v. 
Prometheus.39
The first of these is The Association of Molecular Pathology, et al. v. Myriad Genetics, 
Inc., et al. in which the Court made its ruling on March 26, 2012. The case involves the 
patentability of isolated human DNA. Although the claim relates to a composition of 
matter and not a process as in Mayo v. Prometheus, it could reasonably be adjudged as 
a claim on a natural phenomenon and therefore patent-ineligible.
The second is WildTangent v. Ultramercial,40 in which the Court made its ruling on 
May 21, 2012. The patent in this case involves a claimed process for a specific mode of 
distributing copyrighted content on the internet.41
39  At the time of writing this, a few other petitions for certiorari relating to patent-
eligibility remain pending. Among these are Fort Properties v. American Master Lease, 
Accenture Global v. Guidewire and Bancorp Services v. Sun Life.
40  The judgment of the U.S. Court of Appeals for the Federal Circuit is reported at 657 F.3d 
1323
41  Claim 1 of the patent at issue as quoted in the judgment of the U.S. Court of Appeals for 
the Federal Circuit is as follows:
A method for distribution of products over the Internet via a facilitator,
said method comprising the steps of:
  a first step of receiving, from content provider, media products that        
are covered by intellectual property rights protection and are available
for purchase, wherein each said media product being comprised of at 
least one of text data, music data, and video data;
  a second step of selecting a sponsor message to be associated with the
media product, said sponsor message being selected from a plurality of 
sponsor messages, said second step including accessing an activity log to
verify that the total number of times which the sponsor message has been
previously presented is less than the number of transaction cycles contracted
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III. The International Position Relating to Patent Subject Matter Eligibility:
The fostering of industrial innovation is an important factor in achieving and 
promoting competitiveness in the global arena. Intellectual property rights, and patent 
rights in particular, play a vital role in shaping a culture in which creativity and 
innovation can thrive. As one of the Amicus Curiae briefs in the case has accurately 
stated:
The United States has been historically, and remains currently,
a leader in innovation. Manufacturing, chemistry, electronics, 
biotechnology, and computer software are just a few of the 
technological fields that have seen tremendous commercial 
development within the United States. The Patent Laws of the
United States have accommodated and fostered innovation in
and development of all these technologies, and have helped the
United States to achieve and maintain its position in the 
by the sponsor of the sponsor message;
  a third step of providing the media product for sale at an Internet website;
  a fourth step of restricting general public access to said media product;
  a fifth step of offering to a consumer access to the media product without
charge to the consumer on the precondition that the consumer views the 
sponsor message;
  a sixth step of receiving from the consumer a request to view the sponsor
message, wherein the consumer submits said request in response to being
offered access to the media product;
  a seventh step of, in response to receiving the request from the consumer, 
facilitating the display of a sponsor message to the consumer;
  an eighth step of, if the sponsor message is not an interactive message, 
allowing said consumer access to said media product after said step of 
facilitating the display of said sponsor message;
  a ninth step of, if the sponsor message is an interactive message, presenting
at least one query to the consumer and allowing said consumer access to said
media product after receiving a response to said at least one query;
  a tenth step of recording the transaction event to the activity log, said 
tenth step including the total number of times the sponsor message has been
presented, and
  an eleventh step of receiving payment from the sponsor of the sponsor
message displayed.
657 F.3d 1323 at 1324, 1325. 
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global economy.42 
Because of the transnational effects of patent law, and the benefit to free trade and 
other aspects of international cooperation that can flow from harmonization of patent 
laws among the nations of the world, efforts have been made in this direction since 
1883. Some of the principal international treaties relating to harmonization are the 
Paris Convention for the Protection of Industrial Property, the Convention Establishing 
the World Intellectual Property Organization, the Patent Cooperation Treaty, the 
Convention On the Unification Of Certain Points of Substantive Law On Patents for 
Invention, the Convention On the Grant Of European Patents, and the Agreement on 
Trade-Related Aspects of Intellectual Property Rights (TRIPS), the Patent Law Treaty 
and the Substantive Patent Law Treaty.
The most important of the international treaties relating to intellectual property 
rights is the TRIPS agreement which is administered under the aegis of the World 
Trade Organization.
The Scope of patentable subject matter under the TRIPS agreement is contained in 
Article 27 in the chapter entitled: “Part II Standards Concerning the Availability, Scope 
and Use of Intellectual Property Rights.” Sub-clause 3 (a) of Article 27 specifically 
makes “diagnostic, therapeutic and surgical methods for the treatment of humans and 
animals” excludable from the ambit of patentable subject matter.43 So also, the 
42  Brief of Amici Curiae Association Internationale Pour La Protection De La Propriete 
Intellectuelle and International Association For the Protection Of Intellectual Property 
(U.S.) In Support of Neither Party, at pages 3 and 4. Available at SCOTUS blog, supra 
note 34. 
43  The entire Article 27 of the TRIPS agreement states as follows:
  1.Subject to the provisions of paragraphs 2 and 3, patents shall be 
for any inventions, whether products or processes, in all fields of technology,
provided that they are new, involve an inventive step and are capable of
industrial application. Subject to paragraph 4 of Article 65, paragraph 8
of Article 70 and paragraph 3 of this Article, patents shall be available and
patent rights enjoyable without discrimination as to the place of invention,
the field of technology and whether products are imported or locally 
produced.
  For the purposes of this Article, the terms “inventive step” and “capable
of industrial application” may be deemed by a Member to be synonymous
with the terms “non-obvious” and “useful” respectively.
  2. Members may exclude from patentability inventions, the prevention
within their territory of the commercial exploitation of which is necessary
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Handbook of the World Intellectual Property Organization lists “methods of treatment 
for humans or animals, or diagnostic methods practiced on humans or animals,” as 
among the items that are excludable from the ambit of patentable subject matter.44 
Following is a description of the scope of subject matter patent-eligibility in Japan 
and the member states of the European Patent Organization.
1. Subject matter patent eligibility in Japan:
The important factors for determining subject matter patent eligibility in Japan are 
to protect ordre public or morality, including to protect human, animal or
plant life or health or to avoid serious prejudice to the environment,
provided that such exclusion is not made merely because the exploitation
is prohibited by their law.
  3. Members may also exclude from patentability:
(a) diagnostic, therapeutic and surgical methods for the treatment of
humans or animals;
(b) plants and animals other than micro-organisms, and essentially
biological processes for the production of plants or animals other than
non-biological and microbiological processes. However, Members shall 
provide for the protection of plant varieties either by patents or by an 
effective sui generis system or by any combination thereof. The 
provisions of this subparagraph shall be reviewed four years after the
date of entry into force of the WTO Agreement.
 Available at http://www.jpo.go.jp/shiryou_e/s_sonota_e/fips_e/trips/ta/chap3.htm.
44  See Article 2.7 of the WIPO Intellectual Property Handbook: Policy, Law and Use, available at 
http://www.wipo.int/export/sites/www/about-ip/en/iprm/pdf/ch2.pdf.
 The entire Article 2.7 reads as follows:
  2.7 In order to be eligible for patent protection, an invention must fall
within the scope of patentable subject matter. Patentable subject matter
is established by statute, and is usually defined in terms of the exceptions
to patentability, the general rule being that patent protection shall be
available for inventions in all fields of technology (see Article 27.1 of the
TRIPS Agreement).
  2.8 Subject matter which may be excluded from patentability includes
the following (see also Article 27.3 of the TRIPS Agreement). Examples
of fields of technology which may be excluded from the scope of patentable
subject matter includes the following:
 discoveries of materials or substances already existing in nature;
- scientific theories or mathematical methods;
- plants and animals other than microorganisms, and essential
 biological processes for the production of plants and animals, 
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set out in the Examination Guidelines for Patent Utility Model in Japan.45 Article 29 (1) of 
the Patent Act of Japan requires that in order to be patentable, an invention should be 
“industrially applicable.” Among the inventions listed in the Guidelines as unpatentable 
are: 
“(1) A law of nature as such...
  (2) Mere discoveries and not creations...
  (3) Those contrary to a law of nature...
  (4) Those in which a law of nature is not utilized...
  (5) Those not regarded as technical ideas...
  (6) Those for which it is clearly impossible to solve the problem...
 to be solved by any means presented in a claim.”46 
Among the “List of Industrially Inapplicable Inventions” are “methods of surgery, 
therapy or diagnosis of humans.”47 Further, “methods of diagnosis of humans” is listed 
among “types of methods considered to be classified as ‘methods of surgery, therapy 
or diagnosis of humans.”48 
These provisions indicate that the sort of medical process at issue in Mayo v. 
Prometheus would be considered patent-ineligible subject matter.
2. The Member States of the European Patent Organization:
What constitutes patent-eligible subject matter is set out in Articles 52 and 53 of 
the European Patent Convention.49 Article 52 describes the ambit of “Patentable 
Inventions” thus:
(1) European patents shall be granted for any inventions, in all
 fields of technology, provided that they are new, involve an inventive
 other than non-biological and microbiological processes;
- schemes, rules or methods, such as those for doing business,
 performing purely mental acts or playing games;
- methods of treatment for humans or animals (but not products
 for use in such methods).
45  Examination Guidelines for Patent and Utility Model in Japan, available at http://www.jpo.
go.jp/cgi/linke.cgi?url=/tetuzuki_e/t_tokkyo_e/1312-oo2_e.htm. 
46  Examination Guidelines for Patent and Utility Model in Japan, Id. at internal pages 1, 2, and 3.
47  Id., Clause 2.1 and Clause 2.1.1 at internal page 4.
48  Id., Clause 2.1.1.1 and Clause 2.1.1.1 (3) at internal pages 4 and 5. 
49  The European Patent Convention, available at http://www.epo.org/law-practice/legal-texts/
html/epc/2010/e/ma1.html.
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 step and are susceptible of industrial application.
(2) The following in particular shall not be regarded as inventions
 within the meaning of paragraph 1:
(a) discoveries, scientific theories and mathematical methods;
(b) aesthetic creations;
(c) schemes, rules and methods for performing mental acts, playing
games or doing business, and programs for computers;
(d) presentations of information.
(3) Paragraph 2 shall exclude the patentability of subject-matter or
 or activities referred to therein only to the extent to which a 
 European patent relates to such subject-matter or activities as such.
Article 53 then lists the “Exceptions to patentability” thus:
European patents shall not be granted in respect of:
(a) inventions the commercial exploitation of which would be 
contrary to “ordre public” or morality; such exploitation shall not
be deemed to be so contrary merely because it is prohibited
by law or regulation in some or all of the Contracting States;
(b) plant or animal varieties or essentially biological processes
for the production of plants or animals; this provision shall 
not apply to microbiological processes or the products thereof;
(c) methods for treatment of the human or animal body by
surgery or therapy and diagnostic methods practiced on the 
human or animal body; this provision shall not apply to products,
in particular substances or compositions, for use in any of 
these methods.
Article 53 (c) indicates that the patent at issue in Mayo v. Prometheus would not be 
considered to be patent eligible under the European Patent Convention.50
50  It is important to note the Opinion of the Enlarged Board of Appeal at the European 
Patent Office delivered in December 2005, in Case G 0001/4, available at: http://www.
epo.org/law-practice/case-law-appeals/pdf/g040001ex1.pdf. The Enlarged Board held that 
a diagnostic method will be excluded from patentability only if all the technical method 
steps that are constitutive for making the diagnosis must be performed on the human or 
animal body. If even one of the constitutive steps is not performed on the human or 
animal body, then the method is patentable under the European Patent Convention.
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IV. Some Brief Comments and Observations About the Court’s Opinion in 
Mayo v. Prometheus:
1. Justice Breyer’s opinion pays attention, albeit in passing, to the international 
aspect of the issue.51 Due to the forces of globalization, national patent laws have 
international ramifications. This has been one of the factors impelling the drive to 
bring about the international harmonization of patent laws. The U.S. Congress has 
implicitly recognized the importance of harmonization.52 The opinion has the effect of 
bringing the U.S. law in respect of patentability of medical diagnostic techniques in 
closer alignment with that of most other countries.53 
2. The Court’s opinion is in keeping with the intent of Congress in enacting 
Section 287 (c) of the United States Patent Act, which exempts from liability medical 
practitioners who in performing a medical activity infringe a medical method patent.54 
Harmonization with international law and practices was at least one of the motivating 
51  Mayo v. Prometheus, supra note 2, at pages 23 and 24 of the slip opinion, the opinion cites 
one of the Amicus Curiae briefs to the effect that “research leading to the discovery of 
laws of nature, is expensive; it ‘ha[s] made the United States the world leader in this 
field’; and it requires protection.” And later, the opinion cites another of the amicus 
curiae briefs for the information that “methods of medical treatment are not patentable 
in most of Western Europe.”
52  See, for example, Section 3 (p) of the “Leahy-Smith America Invents Act.,” available at 
http://www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf. With reference to the 
conversion to a “first inventor to file” system, the section expresses the “sense of 
Congress” that doing so would “promote harmonization of the United States patent 
system with the patent systems commonly used in nearly all other countries throughout 
the world ... and thereby promote greater international uniformity and certainty in the 
procedures used for securing the exclusive rights of inventors to their discoveries.”
53  See Brief of Amici Curiae Association Internationale Pour La Protection De La Propriete 
Intellectuelle And International Association for the Protection of Intellectual Property 
(U.S.) In Support of Neither Party, at A 16 (“Methods of medical treatment are only 
patentable subject matter in Australia and in the States. In all other reporting countries 
methods of medical treatment are not patentable.”) Available at SCOTUS Blog, supra 
note 36.
54  35 U.S.C. 287©(1)-(2) (2004); Omnibus Consolidated Appropriations Act of 1996 Section 
616, Pub. L. 104-208, 110 Stat., 3009 (codified as 35 U.S.C. Section 287 (c) (1994) Supp. 
II 1996 & Supp. IV 1998). The Bill in the Senate for the enactment of Section 287 (c) 
was entitled: “S.1334 –A bill to amend chapter 28 of title 35, United States Code, to 
provide form noninfringing uses of patents on medical and surgical procedures.”
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factors behind the enactment of 35 U.S. 287 (c).55 The Court’s opinion furthers this 
intent. 
3. Intellectual Property laws and Competition law have antithetical concerns. 
While intellectual property laws serve to promote innovation and creativity, they tend 
to inhibit the sort of competition that competition law seeks to promote. At their core 
both serve the public good.56 The Court’s Opinion in Mayo v. Prometheus does not 
directly deal with the tension between intellectual property law and antitrust or 
competition law. However, it does take due cognizance of the negative effects of the 
exclusive nature of rights conferred by patent law. The Opinion notes:
Patent protection is, after all, a two-edged sword. On the one
hand, the promise of exclusive rights provides monetary 
incentives that lead to creation, invention, and discovery. On 
the other hand, that very exclusivity can impede the flow of 
information that might permit, indeed spur, invention, by for
example, raising the price of using the patented ideas once
created, requiring potential users to conduct costly and time-
consuming searches of existing patents and pending patent
applications, and requiring the negotiation of complex licensing
arrangements.57 
Even as it recognized these contradictory effects, the Court did not base its opinion 
on a resolution of this tension in this specific case because of the consequential 
difficulties that could result in cases of patents in other unrelated areas. By doing so, 
the Court deftly avoided obfuscating further the already contentious area of subject-
matter patent eligibility. 
4. The Court’s “law of nature” rationale has the potential effect of rendering a 
large swath of innovations related to biotechnology and pharmaceuticals ineligible for 
55  See U.S. Patent and Trademark Office, “Notice of Hearings and Request for Comments 
on Issues Relating to Patents Protection for Therapeutic and Diagnostic Methods,” 61 
Fed. Reg. at 103200-23.
56  For a detailed discussion of the conflicting aims of intellectual property law and 
competition law, see: U.S. Dept of Justice and Federal Trade Comm’n, Antitrust 
Enforcement and Intellectual Property Rights: Promoting Innovation and Competition 
(2007). Available at: http://www.ftc.gov/reports/innovation/PO40101PromotingInnovatio
nandCompetitionrpt0704.pdf.
57  Mayo v. Prometheus, supra note 2, at internal page 23.
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patent protection. The actual consequences of the Court’s judgment will be known 
only after a passage of time. However, the intuitive response of most people is that the 
judgment is beneficial from the viewpoint of the provision of health care and thereby 
in the interest of the larger public good. It will also have the salutary effect of reining 
in an overgenerous grant of patents granted in recent years by the USPTO.
V. Conclusion:
Thus, the judgment of the U.S. Supreme Court in the case of Mayo Collaborative 
Services v. Prometheus Laboratories, Inc. is a major step in the Court’s evolving 
jurisprudence relating to subject matter patent eligibility and particularly in the area of 
medical diagnostics. The judgment is likely to have a major impact on the 
biotechnology and pharmaceutical industries. It will also have a bearing on the 
provision of health care to individuals. Medical practice and the freedom of doctors to 
use therapeutic techniques that are most suited to the needs of the particular individual 
in need of such care will also be greatly enhanced. The Mayo ruling will also serve as 
an important precedent in the resolution of important biotechnology related cases 
presently pending before the courts. The outcome of those cases will be eagerly 
watched as the emerging doctrine relating to subject matter eligibility evolves and 
assumes a clearly delineated shape and form. 
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　米国連邦最高裁は、2012年3月20日のMayo Collaborative Services v. Prometheus 
Laboratories, Inc.の判例において、十分に予測された判決を打ち出した。その判決は、そ
の決議の賛否両方の法学者や法実践者から多くの意見を引き起こした。一つ合意していた点
は、主題特許可能性と関係のある法律を再構成するものである限り、最高裁の判決は非常に
重要である、ということである。Mayo v. Prometheusのケースでは、自己免疫疾患治療の
チオプリン（thiopurine）という合成薬の適切な投与量を決める、医学的な工程に特許が関
わっている。判決は、バイオテクノロジーと製薬業界にとって、確かに大きな意味を持つも
のであり、ヘルスケアと医学的診断のテクニックの分野においても影響を持つものであろう。
それはまた、コンピューターをベースにしたビジネス方法とソフトウエア関連の特許などの
他の方法特許においても、重要なつながりを持ちうるものであろう。重要な判例となった主
題特許可能性に関わる方針や原則を広げていくと、最高裁は米国特許法第101条の下、特許
可能性の除外に関わる基準を明確化している。この論文では、Mayo v. Prometheusの判決
にならって形作られてきた、主題特許可能性とそのような可能性の輪郭に関わる米国最高裁
の法理の発展を述べている。特許法での国を超えた反響のために、この論文では特許法に関
する2つの他の主な分野、つまり日本とEuropean Patent Organisationの加盟各国の主題特
許可能性に関わる法律の立場を述べている。最後にこの論文ではその判決に関する個人的な
所見や意見を述べている。

